Myriad Genetics, Inc.
MYGN
$3.84
-$0.27-6.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -101.40M | -127.30M | -116.00M | -155.20M | -234.60M |
| Total Depreciation and Amortization | 59.90M | 61.20M | 61.50M | 54.30M | 52.50M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 81.00M | 111.80M | 56.00M | 62.50M | 55.10M |
| Change in Net Operating Assets | -45.90M | -54.40M | -71.50M | -54.40M | 30.70M |
| Cash from Operations | -6.40M | -8.70M | -70.00M | -92.80M | -96.30M |
| Capital Expenditure | -17.60M | -19.00M | -25.40M | -32.80M | -46.40M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 8.80M | 8.80M | 8.80M | -- | -- |
| Other Investing Activities | -4.30M | -1.70M | -1.40M | 4.80M | 36.60M |
| Cash from Investing | -13.10M | -11.90M | -18.00M | -28.00M | -9.80M |
| Total Debt Issued | 100.00M | 120.00M | 140.00M | 120.00M | 140.00M |
| Total Debt Repaid | -80.40M | -119.90M | -140.40M | -120.40M | -100.30M |
| Issuance of Common Stock | 5.90M | 5.90M | 126.60M | 126.60M | 123.60M |
| Repurchase of Common Stock | -10.50M | -13.40M | -13.70M | -12.90M | -12.60M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00K | -300.00K | -1.70M |
| Cash from Financing | 15.00M | -7.40M | 112.40M | 113.00M | 149.00M |
| Foreign Exchange rate Adjustments | -100.00K | -1.00M | 400.00K | -1.40M | -400.00K |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | 0.00 | -2.30M | -- |
| Net Change in Cash | -4.60M | -29.00M | 24.80M | -11.50M | 42.50M |